In December 2025, announced initial preclinical results from the company’s novel, potent, selective JAK2 V617F inhibitor CGT1145 at the ASH annual meeting. These results showcased greater than ...

TransCon Growth Hormone or TransCon hGH is now approved in the US by the FDA for the replacement of endogenous growth hormone ...

The “Illinois Homelessness Mortality and Morbidity Report” confirms what outreach workers have long known: Homelessness is a terminal diagnosis.

Q4 2025 Earnings Call February 11, 2026 4:30 PM ESTCompany ParticipantsChad Fugure - Vice President of Investor ...

The critical factor in elevating the current environment to one of crisis is liquidity in the market and the availability of ...

The final bullet reads: “Mr. Epstein has never re-negged [sic] on a trade in over thirty years. He has never claimed against a bad trade in thirty years. This can be confirmed with Ace Greenburg [sic] ...

Q4 2025 product revenue of €240 million and FY 2025 product revenue of €684 millionQ4 2025 operating profit of €10 million and cash flow from ...

Thank you for joining our first quarter fiscal year 2026 earnings call. Veru Inc. is a late clinical-stage biopharmaceutical company focused on developing novel medicines for the treatment of ...

The AI-fueled chip crisis has reportedly upended Sony and Nintendo’s console plans, and may cause a delay to the release of ...

Whether a film is good, bad or indifferent, Mishra leaves an indelible mark. His performance is sometimes concentrated in a face that can summon mobility as well as reserve. The effect can be sonic ...

By David Bautz, PhD NASDAQ:ARWR READ THE FULL ARWR RESEARCH REPORT Business Update First Commercial Sales of REDEMPLO® ...

After saying I was going to try out ClassPass for months and months, I finally did it. Is there any better way to kick off 2026 by taking advantage of something that is completely free? I don’t think ...